Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
As a Jew, I don't feel that what this company is doing is racist. The
difference, though, between the Israeli doctors, and American Jews is the
American mentality. Patenting a test that "costs more" than what would
normally cost much less, is a normal thing out here. Look at the cost of
any specialized test that doctors use out here, before insurance.
With that said, I do agree that the test should not be given an
International patent, due to the number of people affected, and the
difference in costs. A patent that's local to America would be OK, and in
the norm, since peoples' insurance would soak up the inflated costs and
would be more of the same that we expect of this "great" nation.
Racist? Doubtful...
As a Jew, I don't feel that what this company is doing is racist. The
difference, though, between the Israeli doctors, and American Jews is the
American mentality. Patenting a test that "costs more" than what would
normally cost much less, is a normal thing out here. Look at the cost of
any specialized test that doctors use out here, before insurance.
With that said, I do agree that the test should not be given an
International patent, due to the number of people affected, and the
difference in costs. A patent that's local to America would be OK, and in
the norm, since peoples' insurance would soak up the inflated costs and
would be more of the same that we expect of this "great" nation.
Competing interests:
None declared
Competing interests: No competing interests